Schrödinger Inc.
(SDGR)
undefined
undefined%
At close: undefined
20.83
0.12%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications.
The company operates in two segments, Software and Drug Discovery.
The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.
The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide.
Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger Inc.
Country | United States |
IPO Date | Feb 6, 2020 |
Industry | Medical - Healthcare Information Services |
Sector | Healthcare |
Employees | 900 |
CEO | Dr. Ramy Farid Ph.D. |
Contact Details
Address: 1540 Broadway New York, New York United States | |
Website | https://www.schrodinger.com |
Stock Details
Ticker Symbol | SDGR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001490978 |
CUSIP Number | 80810D103 |
ISIN Number | US80810D1037 |
Employer ID | 95-4284541 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Ramy Farid Ph.D. | Chief Executive Officer, President & Director |
Dr. Geoffrey Craig Porges MBBS | Executive Vice President & Chief Financial Officer |
Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software |
Shane Brauner | Executive Vice President & Chief Information Officer |
Dr. Karen Akinsanya Ph.D. | President of Research & Development Therapeutics |
Dr. Margaret Han Dugan M.D. | Chief Medical Officer |
Dr. Richard A. Friesner Ph.D. | Co-Founder, Scientific Advisory Chairman and Director |
Dr. Robert Lorne Abel Ph.D. | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D |
Jaren Irene Madden | Senior Vice President of Investor Relations & Corporate Affairs |
Prof. William Goddard III | Co-Founder & Scientific Advisor |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 12, 2024 | 10-Q | Quarterly Report |
Oct 16, 2024 | 4 | Filing |
Sep 12, 2024 | 8-K | Current Report |
Jul 31, 2024 | S-8 | Filing |
Jul 31, 2024 | 10-Q | Quarterly Report |
Jul 31, 2024 | 8-K | Current Report |
Jun 20, 2024 | 4 | Filing |
Jun 20, 2024 | 4 | Filing |
Jun 20, 2024 | 4 | Filing |